Warfarin sodium

• CAT Number: I010068
• CAS Number: 129-06-6 (sodium salt)
• Molecular Formula: C19H15NaO4
• Molecular Weight: 330.31477
• Purity: ≥95%
• Solubility: Soluble in DMSO, not in water
• Storage: 0 - 4 °C for short term, or -20 °C for long term
• InChI: InChI=1S/C19H16O4.Na/c1-12(20)11-15(13-7-3-2-4-8-13)17-18(21)14-9-5-6-10-16(14)23-19(17)22;/h2-10,15,21H,11H2,1H3;/q;+1/p-1
• InChIKey: KYITYFHKDODNCQ-UHFFFAOYSA-M
• SMILES: CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)[O-].[Na+]

Warfarin is an anticoagulant normally used in the prevention of thrombosis and thromboembolism, the formation of blood clots in the blood vessels and their migration elsewhere in the body, respectively. It was initially introduced in 1948 as a pesticide against rats and mice, and is still used for this purpose, although more potent poisons such as brodifacoum have since been developed. In the early 1950s, warfarin was found to be effective and relatively safe for preventing thrombosis and thromboembolism in many disorders. It was approved for use as a medication in 1954, and has remained popular ever since. Warfarin is the most widely prescribed oral anticoagulant drug in North America.

Reference

1:Evaluation of In-Use Stability of Anticoagulant Drug Products: Warfarin Sodium. Nguyenpho A, Ciavarella AB, Siddiqui A, Rahman Z, Akhtar S, Hunt R, Korang-Yeboah M, Khan MA.J Pharm Sci. 2015 Dec;104(12):4232-40. doi: 10.1002/jps.24657. Epub 2015 Oct 26. PMID: 26501849 2:Understanding effect of formulation and manufacturing variables on the critical quality attributes of warfarin sodium product. Rahman Z, Korang-Yeboah M, Siddiqui A, Mohammad A, Khan MA.Int J Pharm. 2015 Nov 10;495(1):19-30. doi: 10.1016/j.ijpharm.2015.08.065. Epub 2015 Aug 28. PMID: 26319638 3:Development and validation of X-ray diffraction method for quantitative determination of crystallinity in warfarin sodium products. Siddiqui A, Rahman Z, Korang-Yeboah M, Khan MA.Int J Pharm. 2015 Sep 30;493(1-2):1-6. doi: 10.1016/j.ijpharm.2015.07.051. Epub 2015 Jul 21. PMID: 26209072 4:Application of NIR chemometric methods for quantification of the crystalline fraction of warfarin sodium in drug product. Korang-Yeboah M, Akhtar S, Siddiqui A, Rahman Z, Khan MA.Drug Dev Ind Pharm. 2016;42(4):584-94. doi: 10.3109/03639045.2015.1058817. Epub 2015 Jul 10. PMID: 26161939 5:Chemometric Model Development and Comparison of Raman and (13)C Solid-State Nuclear Magnetic Resonance-Chemometric Methods for Quantification of Crystalline/Amorphous Warfarin Sodium Fraction in the Formulations. Rahman Z, Mohammad A, Akhtar S, Siddiqui A, Korang-Yeboah M, Khan MA.J Pharm Sci. 2015 Aug;104(8):2550-8. doi: 10.1002/jps.24524. Epub 2015 Jun 10. PMID: 26096869 6:Structure and stability of warfarin-sodium inclusion complexes formed with permethylated monoamino-β-cyclodextrin. Tárkányi G, Németh K, Mizsei R, Tőke O, Visy J, Simonyi M, Jicsinszky L, Szemán J, Szente L.J Pharm Biomed Anal. 2013 Jan;72:292-8. doi: 10.1016/j.jpba.2012.09.003. Epub 2012 Sep 11. PMID: 23021299 7:Images in emergency medicine. Man with painful skin lesion. Warfarin sodium skin necrosis. Sorensen DM, Eilbert W.Ann Emerg Med. 2010 Mar;55(3):302, 305. doi: 10.1016/j.annemergmed.2009.06.016. No abstract available. PMID: 20171464 8:Warfarin interactions with substances listed in drug information compendia and in the FDA-approved label for warfarin sodium. Anthony M, Romero K, Malone DC, Hines LE, Higgins L, Woosley RL.Clin Pharmacol Ther. 2009 Oct;86(4):425-9. doi: 10.1038/clpt.2009.95. Epub 2009 Jul 8. PMID: 19587643 9:Upper airway obstruction by epiglottis and arytenoids hematoma in a patient treated with warfarin sodium. Ikeda R, Chiba T, Gorai S, Kobayashi T.Auris Nasus Larynx. 2010 Feb;37(1):114-6. doi: 10.1016/j.anl.2009.03.010. Epub 2009 May 1. PMID: 19410398 10:Delayed clinical presentation of hemorrhagic pericardial effusion in a patient receiving warfarin sodium. Hillyard RF.Am J Orthop (Belle Mead NJ). 2007 Oct;36(10):E144-7. Review. No abstract available. PMID: 18033572